Infliximab biosimilar is under clinical development by Celltrion and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis ...

Methods: 200 patients with active PsA unresponsive to previous treatment were randomised to infusions of infliximab 5 mg/kg or placebo at weeks 0, 2, 6, 14, and 22. Patients with inadequate response ...

South Korea’s Celltrion Healthcare has begun a UK trial of its infliximab biosimilar to see if the drug can accelerate recovery from symptoms of COVID-19. The company noted that COVID-19 is ...

Objectives: A large-scale postmarketing surveillance (PMS) study was carried out to determine the safety profile of infliximab in Japanese patients with rheumatoid arthritis (RA). Methods: The PMS ...

We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses to a single dose of a SARS-CoV-2 vaccine. Design Antibody responses and ...

1 Department of Gastroenterology, Sheba Medical Center Tel Hashomer & Sackler School of Medicine, Tel-Aviv University, Ramat Gan, Israel 2 Department of Gastroenterology, Rambam Health Care Campus & ...

The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) was the target of a significant decrease in short interest in the month of ...

Fatigue in IBD 1 year after diagnosis does not appear to be less prevalent even when applying stricter definitions of disease ...